Monitoring Pregnancy Is Key After Wilms’ Treatment

Publication
Article
OncologyONCOLOGY Vol 16 No 11
Volume 16
Issue 11

Women who received radiation therapy for Wilms’ Tumor are at increased risk of complications during pregnancy and, therefore, should be carefully assessed and monitored by their obstetricians. These conclusions were part of a National Wilms’

Women who received radiation therapy for Wilms’ Tumor are at increased risk of complications during pregnancy and, therefore, should be carefully assessed and monitored by their obstetricians. These conclusions were part of a National Wilms’ Tumor Study Group (NWTSG) report published in the Journal of Clinical Oncology (20:2506-2513, 2002). Daniel M. Green, MD, department of pediatrics, Roswell Park Cancer Institute, was the lead author.

"This is the first study to evaluate the risk of increased complicationsof pregnancy due to prior Wilms’ tumor treatment," said Dr. Green."We found that female survivors of Wilms’ tumor who were treated withradiation are at increased risk for early or threatened labor and that theirchildren are more likely to be premature and may be at increased risk of certaincongenital defects. These increased complications were not seen in the partnersof male survivors of Wilms’ tumor who received the same treatment."

Complications and Congenital Malformations

The study was limited to pregnancies of patients or partners of patients whoreceived either no abdominal irradiation or only flank irradiation as part oftheir initial course of treatment. The NWTSG reviewed reports of 427 pregnancieswith a duration of 20 weeks or more, including 409 liveborn singletons. The mostcommon complications identified during pregnancy included malposition of thefetus and early or threatened labor. Offspring of the irradiated women were morelikely to have a low birthweight and be premature (less than 36 weeks’gestation). An increased percentage had one or more congenital malformationssuch as cleft lip and palate, undescended testes, or clubfoot.

"We found that the identified complications were more frequent amongwomen who received a higher radiation therapy dose," said Dr. Green."Additional research is needed to validate these observations and determineif survivors who received lower flank radiation therapy are less likely to havethese complications with a pregnancy. Survivors and their physicians must beaware of these issues when guiding a pregnancy to term."

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content